Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma.

about

Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma.

Item

http://www.wikidata.org/entity/Q55497250

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Nab-paclitaxel is effective ag ...... uption of desmoplastic stroma.

@en

Nab-paclitaxel is effective ag ...... uption of desmoplastic stroma.

@nl

type

Item

label

Nab-paclitaxel is effective ag ...... uption of desmoplastic stroma.

@en

Nab-paclitaxel is effective ag ...... uption of desmoplastic stroma.

@nl

prefLabel

Nab-paclitaxel is effective ag ...... uption of desmoplastic stroma.

@en

Nab-paclitaxel is effective ag ...... uption of desmoplastic stroma.

@nl

P1476

Nab-paclitaxel is effective ag ...... uption of desmoplastic stroma.

@en

P2093

Chun-Nan Yeh

http://www.w3.org/2001/XMLSchema#string

Chun-Yu Liu

http://www.w3.org/2001/XMLSchema#string

Kun-Chun Chiang

http://www.w3.org/2001/XMLSchema#string

Ming-Han Chen

http://www.w3.org/2001/XMLSchema#string

Ming-Huang Chen

http://www.w3.org/2001/XMLSchema#string

Peter Mu-Hsin Chang

http://www.w3.org/2001/XMLSchema#string

Ren-Chin Wu

http://www.w3.org/2001/XMLSchema#string

Ta-Sen Yeh

http://www.w3.org/2001/XMLSchema#string

Yi-Hsiu Chung

http://www.w3.org/2001/XMLSchema#string

P2860

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

Cholangiocarcinoma.

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

Cholangiocarcinoma: a compact review of the literature.

Genetics of biliary tract cancers and emerging targeted therapies.

P304

566-572

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2018.8690

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chi-Tung Cheng

P577

2018-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29963132

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

P932

6019977

http://www.w3.org/2001/XMLSchema#string